Therapeutic agent for soft tissue sarcoma
View Patent ↗A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), contains a histone deacetylase inhibitor (particularly a compound of formula I) as an active ingredient
1. A method for treating soft tissue sarcoma, comprising:
administering an effective amount of a histone deacetylase inhibitor selected from the group consisting of a compound of formula (I)
a thiol form of the compound of formula (I) having a reduced S—S bond, an analog of the compound of formula (I), a prodrug of the compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), a hydrate of the compound of formula (I), an anhydrous form of the compound of formula (I), an acetylated form of the compound of formula (I), a stereoisomer of the compound of formula (I), trichostatin A, sodium butyrate, suberoylanilide hydroxamic acid, MS-275, cyclic hydroxamic acid containing peptide, Apicidin, Trapoxin and mixtures thereof;
wherein the soft tissue sarcoma is synovial sarcoma.
2. The method of claim 1 , wherein the soft tissue sarcoma is synovial sarcoma.
3. The method of claim 2 , wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.
4. The method of claim 1 , wherein the histone deacetylase inhibitor is a compound represented by the formula (II)
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the soft tissue sarcoma is synovial sarcoma.
6. The method of claim 5 , wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.